Salubris gets trial approval for SAL0140 targeting chronic kidney disease

Shenzhen Salubris Pharmaceuticals Co., Ltd. (Salubris) announced it has received a "Notice of Clinical Trial Approval" from the National Medical Products Administration. This approval allows the company to proceed with clinical trials for SAL0140, an innovative small molecule drug, for the treatment of chronic kidney disease (CKD).

SAL0140 is an aldosterone synthase inhibitor developed with proprietary intellectual property by Salubris. The drug is intended to address multiple indications, including uncontrolled hypertension (including difficult-to-treat hypertension), primary aldosteronism, and chronic kidney disease. Aldosterone, a critical mineralocorticoid, is involved in fluid and electrolyte balance and contributes to cardiovascular and renal target organ damage.

The company anticipates that SAL0140, if successfully developed and approved, will expand its innovative product pipeline in the chronic disease sector, offering new treatment options for patients in underserviced areas. Salubris also noted that drug development involves a lengthy and high-risk process, and the clinical trial and market launch phases are subject to various uncertainties, which will not immediately impact the company's short-term performance.